Protocol Ledger

NCT07917780 · Phase II · RECRUITING

A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation

Interventional Phase II clinical trial protocol NCT07917780 sponsored by German CLL Study Group in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-18 Enrollment: 116 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07917780
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)116 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07917780
Protocol FieldVerified Registry Value
NCT IdentifierNCT07917780
Consolidated Lead SponsorGerman CLL Study Group
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment116 participants (ESTIMATED)
Registered Start Date2026-06-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07917780
Hospital Research SiteLocationSite Profile
Medizinische Universität WienVienna, AustriaOpen Hospital Dossier ->
RigshospitaletCopenhagen, DenmarkOpen Hospital Dossier ->
Universitätsklinikum HeidelbergHeidelberg, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI